Earli tackles the #1 problem in the $100B cancer drug market: systemic toxicity. On-target/off-tumor effects force suboptimal dosing, reduced efficacy and sidelining some of the most potent drug classes such as cytokines. Earli's BioAI approach flips this paradigm: Drugs are produced only where needed-in the tumor, by the tumor, against the tumor. Cancer cells become their own drug factories, enabling localized immune activation, even in cold tumors.
This was enabled by three core innovations:
Together, these technologies create a new biological control layer, allowing tumors to self-identify and trigger their own targeted immune attack-achieving specificity beyond current targeted or IO therapies.
Earli plans to enter the clinic by mid-2027 with a Phase 1/2 lung cancer trial. The company is backed by a16z, Khosla, Perceptive, Alex Gorsky, Marc Benioff, Breyer, Emerson Collective, Sands Capital and others. The SAB includes Jim Allison (Nobel Laureate, MD Anderson), Bob Langer (Co-founder Moderna, MIT), Phil Greenberg (Co-founder Juno), Amy Abernethy (frm. Principal Deputy FDA Commissioner), Bill Hait (former J&J EVP Oncology R&D), and Alan Ashworth (President UCSF Cancer Center). The leadership team brings deep gene therapy, LNP, CMC and tech experience; CEO Cyriac Roeding previously led a $250M (11x return) exit.
Who You Are
The Position
This is a general submission form to join the Earli Talent Community. If you are interested in working at Earli but don't see a current opening that aligns with your skills and background we're always on the lookout for great people who are interested in working with us or who are interested in potential upcoming internship opportunities available in our lab.
If interested in applying, please attach a CV or have a well-developed LinkedIn profile for us to be able to assess your background.
We look forward to hearing from you!
| Location | Redwood City, CA |